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Abstract 
To test the importance of the dopamine D2 receptor (DRD2) region in nicotine 
dependence, 150 smokers and 228 controls were genotyped for the DRD2 C957T, 
-141delC and ANKK1 TaqIA polymorphisms (rs6277, rs1799732 and rs1800497, 
respectively).  The -141delC SNP did not show any association but both the C957T and 
TaqIA SNPs showed association at the allele, genotype, haplotype and combined 
genotype levels.  The 957C/TaqI A1 haplotype was more than 3.5 times as likely to be 
associated with nicotine dependence compared with the 957T/TaqI A1 haplotype (P = 
0.003).  Analysis of the combined genotypes of both SNPs revealed that individuals 
who were homozygous for the 957C-allele (CC) and had either one or two copies of the 
TaqI A1-allele were 3.3 times as likely to have nicotine dependence compared to all 
other genotype combinations (P = 0.0003) and that these genotypes accounted for 
approximately 13% of the susceptibility to nicotine addiction in our population.  Our 
findings suggest that the DRD2 C957T polymorphism and the ANKK1 TaqIA 
polymorphism are key contributors to the genetic susceptibility of nicotine dependence.   
 
 
 
 
 
 
 
Keywords:  genetic association; dopamine D2 receptor; ANKK1; addiction; haplotype 
 
3 
 
Page 3 of 24 
1. Introduction 
Smoking is known to cause an increase in dopamine release in the left ventral 
caudate/nucleus accumbens and putamen in humans (Brody et al., 2004), which 
stimulates the mesolimbic reward pathways of the brain (Corrigall et al., 1992; Corrigall 
et al., 1994; Cami et al., 2003).  Various aspects of smoking such as initiation of 
smoking and cigarette consumption levels are also known to be highly heritable, as is 
the heritability of nicotine dependence, estimates of which range from 31% to 75% 
(Vink et al., 2005).  Genes involved in dopamine metabolism within the reward 
pathways of the brain are excellent candidates for genes contributing to the genetic 
component of nicotine dependence.   
Much interest has focussed on the dopamine receptor genes, which are expressed in 
these brain regions (Hurd et al., 2001), particularly the dopamine D2 receptor (DRD2) 
gene (Noble, 2000; 2003).  The DRD2 region of chromosome 11 (11q23) has also been 
linked with cigarette consumption in genome wide linkage analyses although not with 
nicotine dependence unless comorbid with alcohol dependence (Gelernter et al., 2004).  
A number of polymorphisms have been studied in DRD2 but it is interesting that the 
one most commonly tested and referred to as a DRD2 variant, known as the TaqI A 
(rs1800497) polymorphism, was subsequently shown to lie in an adjacent gene named 
the ankyrin repeat and kinase domain containing 1gene (ANKK1) (Dubertret et al., 
2004; Neville et al., 2004).  The TaqI A1 (T) allele has been associated with a variety of 
smoking measures in a number of different studies although such findings are not 
consistent (Ho et al., 2007).  A recent meta-analysis also failed to observe association 
between smoking behaviour and the TaqI A polymorphism (Munafo et al., 2009) but 
reports of association continue to appear (Stapleton et al., 2011).  Other polymorphisms 
within DRD2 include TaqI B (rs1079597), TaqI C (simple tandem repeat), TaqI D 
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(rs1800498), -141delC (rs1799732), and C957T (rs6277), all of which have been 
reported to be associated with aspects of smoking behaviour or response to treatment in 
at least one study (Lerman et al., 2006; Ho et al., 2007; Vandenbergh et al., 2007).  No 
associations have been reported, however, for the exon 8 G/A SNP, rs6276 (Johnstone 
et al., 2004) or SNPs rs6589377, rs4482060, or rs4938023 (Gelernter et al., 2006).   
Given the number of genetic variants found to be associated with nicotine dependence 
and other smoking related phenotypes in the DRD2 region and the lack of consistency 
in replication of many of those associations between studies it is likely that the 
influence of this region is not simple.  Rather than a single variant of substantial effect 
there may be two or more polymorphisms that contribute additively or epistatically, or 
are subject to genotype by environment interaction.   
Here we describe an association study involving individual SNPs and specific 
haplotypes of SNP alleles for three variants spanning this region including -141delC 
(rs1799732) in the promoter of DRD2, C957T (rs6277) 62.8Kb down-stream in exon 7 
of DRD2, and TaqI A (rs1800497) a further 12.6 Kb away in exon 8 of ANKK1 and 
only about 9.5 Kb from the 3’-end of the DRD2 mRNA.   
 
2. Methods 
2.1. Participants 
A total of 150 smokers (Caucasian, age: 43.3±11.1; 68 male, 79 female) were recruited 
for this study through hospital and media advertisements.  Participants were 18 years of 
age or older and had smoked for at least three years and were generally healthy despite 
currently smoking 15 cigarettes or more per day.  All were motivated to reduce smoking 
and had the goal of eventual cessation.  However, all participants had at least one 
serious but unsuccessful attempt at quitting in the previous 24 months.  Patients were 
administered the Fagerstrom test for Nicotine Dependence (Heatherton et al., 1991).   
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The control group consisted of 95 females and 133 males, with a mean age of 36.8 years 
(s.d. + 12.8 years) and were recruited from volunteers from the general public and staff 
and students of the Royal Brisbane Hospital and the Queensland University of 
Technology.  Formal screening for nicotine dependence was not undertaken as this 
control group represents a random sample of the populations tested and comprised non-
smokers and smokers different categories, including nicotine dependent, in ratios 
approximating that of the whole population. 
 
2.2. Genotyping 
TaqI A and -141delC genotyping was performed by restriction fragment length 
polymorphism (RFLP) analysis of PCR products. A genomic sequence of 500 bp of the 
coding region of ANKK1 was amplified by PCR using the forward primer 5-
GCACGTGCCACCATACCC-3 and the reverse primer 5-
TGCAGAGCAGTCAGGCTG -3.  A genomic sequence including 284 bp from the 5-
flanking region and 274 bp from exon 1 of DRD2 was amplified by PCR using forward 
primer 5-ACTGGCGAGCAGACGGTGAGGACCC-3 and reverse primer 5-
TGCGCGCGTGAGGCTGCCGGTTCGG-3.  A total of 5-10 ng of genomic DNA was 
amplified in a PCR master mix containing 0.2 M of forward primer and 0.2 M of 
reverse primer, 1x PCR buffer, 1.5 mM MgCl2, 200 M dNTPs and 1 unit of Platinum 
Taq DNA Polymerase (Invitrogen) in a 25 L volume.  Amplification conditions for the 
TaqI A polymorphism were: Step 1: 94°C for 4 min, Step 2: 94°C for 30 s, Step 3: 68°C 
for 30 s, Step 4: 72°C for 30 s, Steps 2-4 were repeated by 40 cycles followed by 72°C 
for 3 min.  Amplification conditions for the -141delC polymorphism were: Step 1: 95°C 
for 3 min, Step 2: 95°C for 30 s, Step 3: 68°C for 30 s, Step 4: 72°C for 30 s, Steps 2-4 
were repeated 40 times followed by a final 72°C step for 2 min. Amplified PCR 
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fragments were digested with TaqI restriction enzyme or BstNI (New England Biolabs) 
(TaqI A and -141delC, respectively) and digested fragments were visualized via agarose 
gel electrophoresis.   
The DRD2 C957T polymorphism was genotyped as previously described (Lawford et 
al., 2005). 
 
2.3. Statistical analysis 
For each polymorphism, a homogeneity χ2 analysis was employed to test the hypothesis 
of homogeneity of allele frequency distributions between nicotine dependent and 
control populations. An odds ratio with 95% confidence interval (CI) was also 
calculated.  Genotype frequencies were similarly compared between nicotine dependent 
and control populations. However, where an allele was found to be associated with 
nicotine dependence, an extended Mantel-Haenszel test was performed to test for a 
trend to nicotine dependence with increasing copy number (0, 1, or 2) of the allele. 
Odds ratios were calculated relative to the homozygote for the non-associated allele and 
population attributable fractions calculated. Genotype data were entered into JLIN 
v1.6.0 (Carter et al., 2006) to estimate haplotype frequencies.  Haplotype frequencies 
were compared between nicotine dependent and control groups using a homogeneity χ2 
analysis.  Each haplotype with a significant association was analysed in isolation by 
partitioning the χ2 accordingly.  All statistics were carried out using the epidemiological 
software Compare2 v2.17 (Abramson, 2004).  Generated haplotypes were analysed for 
linkage disequilibrium (LD) measures (D' and r2) using the JLIN (Carter et al., 2006). 
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3.  Results 
3.1. C957T genotyping 
In order to find genetic associations between nicotine dependence and SNPs in the 
DRD2 region the C957T polymorphism was genotyped in 228 controls and 150 nicotine 
dependent subjects.  The C957T polymorphism showed association with nicotine 
dependence at the allele level (P = 0.022, Table 1).  The genotypes of both groups are 
displayed in Table 2.  A significant trend in susceptibility to nicotine susceptibility was 
found when analysed under a partially dominant model for C957T (P = 0.024; Mantel-
Haenszel test for trend).  The attributable fraction of the C957T polymorphism was 
calculated using genotypes counting the presence of the C-allele as a risk factor.  The 
attributable fraction, which is the proportion of cases in the study population that would 
not have occurred had the risk factor (risk allele) not have been present, is a useful 
measure to quantify the impact of the allele on the development of nicotine dependence 
(Lappalainen et al., 2002).  The analysis revealed that 14.0% (95% CI = 3.18 to 
24.71%) of the susceptibility to nicotine dependence could be attributed to having the 
CC genotype of the C957T DRD2 polymorphism.  Examination of the ORs for the 3 
genotypes indicates that a C-allele recessive pattern of inheritance exists, i.e. the CT and 
TT genotype ORs are both approximately 1.  Under a C-allele recessive model, i.e. CC 
vs CT plus TT genotypes, the CC genotype was more strongly associated with nicotine 
dependence (2 = 5.716, P = 0.017, OR = 1.82, 95% CI = 1.08 to 3.07). 
 
3.2. TaqIA genotyping 
The TaqIA polymorphism was also found to be significantly associated with nicotine 
dependence at the allele level (P = 0.017, Table 1).  The genotypes of both groups are 
displayed in Table 2.  A significant trend in susceptibility to nicotine dependence was 
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found when analysed under a partially dominant model (P = 0.018).  Examination of the 
ORs for the 3 genotypes indicates that a A1-allele dominant pattern of inheritance 
exists, i.e. the A1A1 and A1A2 genotypes both have similar elevated ORs relative to the 
A2A2 genotype.  When analysed under an A1-dominant model, the A1-containing 
genotypes (A1/A1 and A1/A2) were strongly associated with nicotine dependence (2 = 
6.598, P = 0.010).  Those individuals with an A1-containing genotype were almost 
twice as likely to have nicotine dependence compared to those with the A2A2 genotype 
(OR = 1.75, 95% CI = 1.11 to 2.75).  Calculation of the attributable fraction revealed 
that 18.6% (95% CI = 4.1 to 30.9%) of the susceptibility to nicotine dependence could 
be attributed to having the A1/A1 or A1/A2 genotype of the TaqIA polymorphism.   
 
3.3. -141delC genotyping 
No association with nicotine dependence was observed for the -141delC polymorphism 
at the allele (Table 1) or genotype level (Table 2).   
 
3.4. Haplotype analysis 
As both polymorphisms showed association with nicotine dependence, haplotype 
analysis was also performed for the C957T and TaqIA polymorphisms.  Haplotype 
frequencies for the two SNPs are shown in Table 3.  Overall haplotype frequency was 
highly associated with nicotine dependence (P = 0.0009).  This association was due to 
the over representation of the 957C/TaqI A1 haplotype in nicotine dependent patients.  
The 957C/TaqI A2, 957T/TaqI A2, and the 957T/TaqI A1 haplotypes were not 
significantly associated with nicotine dependence.  The 957C/TaqI A1 haplotype was 
more than three times as likely to be associated with nicotine dependence compared to 
the 957T/TaqI A1 haplotype.  As the 957T/TaqI A1 haplotype is quite rare (6.6% of 
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controls), it is probably more realistic to consider the 957T/TaqI A2 and 957C/TaqI A2 
haplotypes as “normal” risk and the 957T/TaqI A1 haplotype as a “low risk” protective 
haplotype, although it did not reach significance (P = 0.079).  
 
3.5. Linkage disequilibrium  
The TaqI A1 and the 957C-alleles were in partial linkage disequilibrium (LD) in both 
the control population D´ = 0.321 and r2 = 0.029 and the nicotine dependent population 
D´ = 0.676 and r2 = 0.139.  While LD exists in the control population it is significantly 
larger in the nicotine group (Goodness-of-fit χ2 = 11.61, P = 0.003) suggesting a 
functional relationship between alleles not just LD as a consequence of proximity alone.   
Both nicotine dependent and control groups were determined to be in Hardy-Weinberg 
equilibrium based on the respective genotype frequencies of each group.   
 
3.6. Combined C957T and TaqIA genotypes  
The combined genotypes of both the C957T SNP and the TaqIA SNP were scored for 
each individual.  All nicotine dependent patients genotyped for both SNPs so 150 
combined genotypes were obtained, however one control sample failed to genotype for 
C957T and a different sample failed to genotype for TaqIA so only 226 combined 
control genotypes were obtained (Table 4).  As there are 9 possible combined 
genotypes, the counts for each genotype are quite low and none reach significance 
except the CC12 genotype.  People with the CC12 genotype are almost six times as 
likely to have nicotine dependence than those with the TT12 genotype (P = 0.016).  
Examination of the odds ratios in Table 4 reveals that there are two high risk genotypes 
(CC11 and CC12) compared to the remaining low risk genotypes.  When the CC11 and 
CC12genoypes were compared with the rest, people with these genotypes were more 
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than 3 times as likely to have nicotine dependence (χ2 = 12.933, P = 0.0003, OR = 3.32, 
95% CI = 1.61 to 7.11) and the attributable fraction in the population was 12.6% (95% 
C.I. = 5.1% to 19.5%). 
 
4. Discussion 
Analysis of three SNPs in the DRD2 region, including the ANKK1 gene revealed 
associations with nicotine dependence at the allele level for the 957C>T and the TaqI A 
polymorphisms.  At the genotype level, the best significance was reached under a 
recessive model for C957T and a dominant model for TaqI A.  These results are 
consistent with other studies that report the A1 allele of the TaqIA polymorphism and 
the C-allele of the DRD2 C957T to be associated with a range of behavioural and brain 
responses to nicotine in humans (Jacobsen et al., 2006; Lerman et al., 2006; Ho et al., 
2007; Vandenbergh et al., 2007; Perkins et al., 2008a; Perkins et al., 2008b; Wang et al., 
2008).  We did not observe any association with the -141delC polymorphism and 
nicotine dependence in our Australian population.  This is also consistent with other 
studies that have not reported association with -141delC and smoking behaviour 
(Yoshida et al., 2001; Styn et al., 2009).  However, the -141delC polymorphism has 
been associated with response to pharmacotherapy for tobacco dependence (Lerman et 
al., 2006).  
In this study, along with individual associations we also found a haplotype including the 
957C and TaqIA1 alleles to be significantly associated with nicotine dependence.   
In a recent study a protective haplotype including the C957T polymorphism was found 
to be associated with reduced risk to become a smoker (Wernicke et al., 2009). 
Earlier studies have reported that dopamine release in the ventral striatum is highly 
sensitive to nicotine (Brody et al., 2004).  Our results support the hypothesis that a 
defect in the central dopaminergic pathway contributes to nicotine dependence (Grieder 
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et al., 2010) by stimulation of the dopamine reward pathway.  It has long been known 
that Nicotine preferentially stimulates dopamine release in the limbic system of rats 
(Imperato et al., 1986) and it is believed that smoking stimulates the mesocorticolimbic 
circuits of the brain, which is thought to be central in behavioural reward and 
reinforcement (Noble, 2000).  Using DRD2 knockout mice it has been shown that 
signalling at DRD2 is critical in mediating withdrawal aversions in nicotine-dependent 
animals.  One or more polymorphisms in the DRD2 receptor and nearby genes which 
are central to the dopamine system could result in increased production of dopamine 
thus increasing the risk of nicotine dependence.   
Examination of the odds ratios for the C957T polymorphism suggests it follows a 
recessive pattern of inheritance with respect to nicotine dependence.  We describe the 
pattern as recessive because the odds ratio of the heterozygote did not differ from the 
odds ratio of the homozygote for the allele that was not associated with nicotine 
dependence.  In contrast the TaqIA polymorphism appears to follow a dominant mode 
of inheritance for nicotine dependence.  Both observations are consistent with 
inheritance patterns that have previously been observed for these two polymorphisms 
(Lawford et al., 2005; Connor et al., 2007).  Also consistent with this pattern of 
inheritance is the observation that there were two high-risk double genotypes (CC11 
and CC12), i.e. those people who are homozygous for the C957T C-allele and also have 
one or two TaqIA A1-alleles have increased risk of nicotine dependence. 
It is known that these DRD2-associated SNPs are involved in other disorders involving 
dopamine perturbation like schizophrenia, PTSD and alcohol dependence (Lawford et 
al., 2005; Connor et al., 2008; Voisey et al., 2009).  The C957T polymorphism has been 
shown to affect mRNA stability and protein translation of the receptor (Duan et al., 
2003) and affects striatal dopamine D2 binding in healthy subjects (Hirvonen et al., 
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2004).  A common molecular defect in the dopamine pathway is likely to explain some 
of the genetic susceptibility to mental illness and substance misuse.   
Using a general population as controls we were able to calculate attributable risk and 
conclude that 14% of the susceptibility to nicotine dependence could be attributed to 
having the CC genotype of the C957T polymorphism and 18.6% of the susceptibility to 
nicotine dependence could be attributed to having the A1/A1 or A1/A2 genotype of the 
TaqI A polymorphism.  Using combined genotype data we were able to identify two 
high-risk genotypes that are more than 3 times as likely to have nicotine dependence 
and account for almost 13% of the population risk for nicotine dependence.  This 
information provides a good starting point for the development of a test that can 
discriminate those at high and low risk of developing alcohol dependence. 
The sample size for the nicotine dependent group in our study was small and the 
associations will need to be confirmed independently, preferably using a larger sample 
size of nicotine dependent individuals.  However, our significant results are encouraging 
using unselected controls as a more significant association is likely to be found using 
controls screened for smoking behaviours.  In this study, we used an unselected control 
population of unknown smoking status.  Further studies would also benefit from having 
a control group who have never smoked as well as a control group that have been casual 
smokers but who do not have nicotine dependence.   
Considerable evidence suggests the importance of dopamine D2 receptor function in 
nicotine dependence.  This study supports these findings by confirming the associations 
with the C957T (rs6277) and the TaqI A (rs1800497) polymorphisms with nicotine 
dependence.  Further investigation of the DRD2 region may improve understanding of 
the pathophysiology of nicotine dependence which may lead to targeted 
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pharmacogenomic treatment strategies and the ability to discriminate those people who 
are likely to develop nicotine dependence from those who are not.   
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Table 1.  Allele frequencies of C957T, TaqI A, and –141delC polymorphisms of the 
DRD2 region in patients with nicotine dependence compared to controls 
 
Group n Allele frequency 2 P Odds Ratio (95% CIa) 
C957T  C (%) T (%)    
Control 454 193 (42.5) 261 (57.5) 
5.242 0.022 1.41 (1.04 to 1.91) Nicotine 300 153 (51.0) 147 (49.0) 
TaqI A  A1 (%) A2 (%)    
Control 454 77 (17.0) 377 (83.0) 
5.646 0.017 1.55 (1.06 to 2.25) Nicotine 300 72 (24.0) 228 (76.0) 
–141delC  Del (%) Ins (%)    
Control 424 48 (11.3) 376 (88.7) 
0.231 0.631 1.13 (0.67 to 1.94) Nicotine 266 27 (10.2) 239 (89.8) 
a Fisher’s exact confidence interval. 
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Table2.  Individual genotype frequencies of C957T, TaqI A, and –141delC polymorphisms 
of the DRD2 region in patients with nicotine dependence compared to controls 
 
Group n Genotype frequency 2  (P) 
C957T  C/C (%) C/T (%) T/T (%)  
Control 227 40 (17.6) 113 (49.8) 74 (32.6) 6.053* (0.048) 
5.086a (0.024) Nicotine 150 42 (28.0) 69 (46.0) 39 (26.0) 
Odds Ratiob  1.992 P = 0.039 
1.159 
P = 1.000 1.000  
TaqI A  A1/A1 (%) A1/A2 (%) A2/A2 (%)  
Control 227 8 (3.5) 61 (26.9) 158 (69.6) 6.622* (0.036) 
5.605a (0.018) Nicotine 150 7 (4.7) 58 (38.7) 85 (56.7) 
Odds Ratiob  1.626 P = 0.734 
1.767 
P = 0.025 1.000  
–141delC  Del/Del (%) Del/Ins (%) Ins/Ins (%)  
Control 212 4 (1.9) 40 (18.9) 168 (79.2) 0.813 (0.666)c 
0.224a (0.636) Nicotine 133 1 (0.008) 25 (18.8) 107 (80.5) 
Odds Ratiob  0.393 P = 0.735 
0.981 
P = 0.999   
* Likelihood-ratio 2 test . 
a Mantel-Haenszel 2 test for trend. 
b With respect to homozygous genotype of allele not associated with nicotine dependence 
c Likelihood-ratio 2 test .At least one cell has an expected frequency of < 5 
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Table 3.  Haplotype analysis of C957T and TaqI A polymorphisms in patients with nicotine 
dependence 
Haplotype Controls c Nicotine c Odds Ratioa (P) χ2 b P 
957T/TaqI A1 30 11 1 3.087 0.079 
957T/TaqI A2 230 136 1.613 (0.548) 2.225 0.136 
957C/TaqI A2 145 92 1.730 (0.403) 0.167 0.683 
957C/TaqI A1 47 61 3.540 (0.003) 14.471 0.0001 
TOTAL 452 300  16.57 0.0009 
a Odds ratio with respect to 957T/TaqI A1 haplotype which is more commonly associated 
with a normal phenotype. 
b Likelihood ratio 2 test comparing haplotype frequency between groups when all other 
haplotypes were pooled.   
c Haplotypes frequencies were estimated using JLIN.  Note, haplotypes with a missing 
genotype were omitted from the analysis (2 control and no nicotine dependence 
samples).  
 
  
24 
 
Page 24 of 24 
Table 4.  Combined genotype frequencies of the C957T and TaqI A polymorphisms in 
patients with nicotine dependence 
Genotype Control Smokers OR χ2 P 
CC11 4 5 3.333 2.177 0.981** 
CC12 10 22 5.867 9.254 0.016 
CC22 26 15 1.538 0.568 1.000 
CT11 4 2 1.333 0.083 1.000** 
CT12 35 30 2.286 2.502 0.796 
CT22 73 37 1.352 0.347 1.000 
TT11 0 0    
TT12 16 6 1   
TT22 58 33 1.517 0.653 1.000 
Total    17.148 0.016 
** At least one cell has an expected frequency < 5 
 
 
